Tier 2 — strong

Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial

Chan M, Qin Z, Man SC, Lam M, Lai WH, Ng RMK, Lee CK, Wong TL, Lee EHM, Wong HK, Feng Y, Liu L, Han F, Chen EYH, Zhang ZJ
Psychiatry and clinical neurosciences 2022 76(3):77-85

Bibliography

PubMed
PMID 34931749
DOI
10.1111/pcn.13323
Funding
Indexed support: Health and Medical Research Fund. See the publication for grant details.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignRandomized controlled human trial
ModelHuman participants; see population
Sample113 participants; 58 berberine and 55 placebo
InterventionBerberine 600 mg/day versus placebo alongside psychiatric care
Duration12 weeks
EndpointsMetabolic or symptom outcomes; Inflammatory markers; Tolerability

What the study showed, in plain terms

Berberine attenuated antipsychotic-associated weight gain and improved selected metabolic measures. The mean between-group weight difference was modest.

Key findings

  • The reported twelve-week weight difference was approximately -1.08 kg.

What this study can and cannot tell us

Selected medicated population and short follow-up; do not extrapolate to general obesity treatment.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Related papers in the corpus

Tier 2
Berberine improves negative symptoms and cognitive function in patients with chronic schizophrenia via anti-inflammatory effect: a randomized clinical trial
Pu Z et al. · Chinese medicine · 2023
Tier 4
Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin
Qiu Y et al. · Asian journal of psychiatry · 2022
Tier 2
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia
Li M et al. · European archives of psychiatry and clinical neuroscience · 2022
Tier 2
Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients
Li J et al. · Contrast media & molecular imaging · 2022
Tier 2
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
Li M et al. · Psychiatry research · 2021

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology